Ser159

Site Information
LLRERKSsAPSHsSQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448382

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 1 ) , mass spectrometry ( 2 ) , mutation of modification site ( 3 ) , phospho-antibody ( 1 , 2 , 3 ) , western blotting ( 2 )
Disease tissue studied:	breast cancer ( 2 ) , leukemia ( 1 ) , acute lymphocytic leukemia ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 3 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 3 ) , COS (fibroblast) ( 2 ) , MCF-10A (breast cell) [GAB2 (human), transfection] ( 2 ) , MCF-10A (breast cell) ( 2 ) , MCF-7 (breast cell) ( 3 ) , MUTZ-5 (B lymphocyte) ( 1 )

Downstream Regulation
Effects of modification on GAB2:	molecular association, regulation ( 3 )
Effects of modification on biological processes:	cell growth, altered ( 3 )
Inhibit interaction with:	HER2 (human) ( 3 ) , SHC1 (human) ( 3 )

References
1	Koschut D, et al. (2020) RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. Oncogene 33247204 Curated Info
2	Brummer T, et al. (2008) Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J 27, 2305-16 19172738 Curated Info
3	Lynch DK, Daly RJ (2002) PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2. EMBO J 21, 72-82 11782427 Curated Info